Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid Hedenfalk

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Molecular Pharmacology|October 25, 2012
Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cellsAstrid Ottosson-Wadlund, Rebecca Ceder, Giulio Preta, et al.
Plos One|September 17, 2014
Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypesJenny-Maria Jönsson, Ida Johansson, Mev Dominguez-Valentin, et al.
Molecular Oncology|April 27, 2024
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancerThomas Fleischer, Mads Haugland Haugen, Jørgen Ankill, et al.
Oncotarget|September 17, 2015
Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implicationsSiker Kimbung, Anikó Kovács, Anna Danielsson, et al.
Breast Cancer Research and Treatment|November 30, 2010
High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancerIda Johansson, Cecilia Nilsson, Pontus Berglund, et al.
Cancers|August 26, 2022
How Reliable Are Gene Expression-Based and Immunohistochemical Biomarkers Assessed on a Core-Needle Biopsy? A Study of Paired Core-Needle Biopsies and Surgical Specimens in Early Breast CancerHani Saghir, Srinivas Veerla, Martin Malmberg, et al.
JCO Precision Oncology|May 26, 2021
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast CancersMads H Haugen, Ole Christian Lingjærde, Ingrid Hedenfalk, et al.
Genes & Development|January 30, 2019
Afadin cooperates with Claudin-2 to promote breast cancer metastasisSébastien Tabariès, Alexander McNulty, Véronique Ouellet, et al.
Gynecologic Oncology|October 9, 2020
High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancerSara Corvigno, Artur Mezheyeuski, Laura Martin De La Fuente, et al.
International Journal of Cancer|September 24, 2017
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trialSiker Kimbung, Ida Markholm, Judith Bjöhle, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Molecular Pharmacology|October 25, 2012
Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cellsAstrid Ottosson-Wadlund, Rebecca Ceder, Giulio Preta, et al.
Plos One|September 17, 2014
Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypesJenny-Maria Jönsson, Ida Johansson, Mev Dominguez-Valentin, et al.
Molecular Oncology|April 27, 2024
An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancerThomas Fleischer, Mads Haugland Haugen, Jørgen Ankill, et al.
Oncotarget|September 17, 2015
Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implicationsSiker Kimbung, Anikó Kovács, Anna Danielsson, et al.
Breast Cancer Research and Treatment|November 30, 2010
High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancerIda Johansson, Cecilia Nilsson, Pontus Berglund, et al.
Cancers|August 26, 2022
How Reliable Are Gene Expression-Based and Immunohistochemical Biomarkers Assessed on a Core-Needle Biopsy? A Study of Paired Core-Needle Biopsies and Surgical Specimens in Early Breast CancerHani Saghir, Srinivas Veerla, Martin Malmberg, et al.
JCO Precision Oncology|May 26, 2021
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast CancersMads H Haugen, Ole Christian Lingjærde, Ingrid Hedenfalk, et al.
Genes & Development|January 30, 2019
Afadin cooperates with Claudin-2 to promote breast cancer metastasisSébastien Tabariès, Alexander McNulty, Véronique Ouellet, et al.
Gynecologic Oncology|October 9, 2020
High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancerSara Corvigno, Artur Mezheyeuski, Laura Martin De La Fuente, et al.
International Journal of Cancer|September 24, 2017
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trialSiker Kimbung, Ida Markholm, Judith Bjöhle, et al.
Pageof 7